Chlorpyrifos PBPK/PD model for multiple routes of exposure

Xenobiotica

Volumn 44, Issue 10, 2014, Pages 868-881

  Poet, Torka S ^a   Timchalk, Charles ^b   Hotchkiss, Jon A ^c   Bartels, Michael J ^c  

^a LLP   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c DOW CHEMICAL COMPANY   (United States)

Author keywords

Chlorpyrifos; Multi route; PBPK

Indexed keywords

CHLORPYRIFOS; INSECTICIDE;

ARTICLE; BIOLOGICAL ACTIVITY; BIOLOGICAL MODEL; BIOLOGICAL MONITORING; EXPOSURE; HUMAN; LUNG MODEL; METABOLIC ACTIVATION; METABOLISM; NONHUMAN; PARALLEL DESIGN; PHYSIOLOGICALLY BASED PHARMACOKINETIC PHARMACODYNAMIC MODEL; VALIDATION STUDY; ADULT; ANIMAL; ENVIRONMENTAL EXPOSURE; MIDDLE AGED; NORMAL HUMAN; RAT; YOUNG ADULT;

ADULT; ANIMALS; CHLORPYRIFOS; ENVIRONMENTAL EXPOSURE; HEALTHY VOLUNTEERS; HUMANS; INSECTICIDES; MIDDLE AGED; MODELS, BIOLOGICAL; RATS; YOUNG ADULT;

EID: 84907056832     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.918295     Document Type: Article

References (67)

1. Albers JW, Garabrant DH, Berent S, Richardson RJ. (2010). Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers. J Exposure Sci Environ Epidemiol 20:79-89
2. Becker RA, Hays SM, Robison S, et al. (2012). Development of screening tools for the interpretation of chemical biomonitoring data. J Toxicol 2012:941082
3. Beydon D, Payan J-P, Grandclaude M-C. (2010). Comparison of percutaneous absorption and metabolism of di-n-butylphthalate in various species. Toxicol In Vitro 24:71-8
4. Bradman A, Whitaker D, Quiro L, et al. (2007). Pesticides and their metabolites in the homes and urine of farmworker children living in the Salinas Valley, CA. J Expo Sci Environ Epid 17:331-49
5. Brown RP, Delp MD, Lindstedt SL, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Indus Health 13:407-84
6. Busby-Hjerpe AL, Campbell JA, Smith JN, et al. (2010). Comparative pharmacokinetics of chlorpyrifos versus its major metabolites following oral administration in the rat. Toxicology 268:55-63
7. Carr RL, Chambers JE. (1996). Kinetic analysis of the in vitro inhibition, aging, and reactivation of brain acetylcholinesterase from rat and channel catfish by paraoxon and chlorpyrifos-oxon. Toxicol Appl Pharmacol 139:365-73
8. Carr RL, Chambers HW, Guarisco JA, et al. (2001). Effects of repeated oral postnatal exposure to chlorpyrifos on open-field behavior in juvenile rats. Toxicol Sci 59:260-7
9. Chambers JE, Chambers HW. (1989). Oxidative desulfuration of chlorpyrifos, chlorpyrifos-methyl, and leptophos by rat brain and liver. J Biochem Toxicol 4:201-3
10. Corbo DC, Liu JC, Chien YW. (1989). Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res 6:848-52
11. Dahl AR, Hadley WM. (1991). Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit Rev Toxicol 21:345-72
12. Du Bois D, Du Bois EF. (1916). A formula to estimate the approximate surface area if height and weight be known. Arch Internal Med 17: 863-71
13. Egeghy PP, Cohen Hubal EA, Tulve NS, et al. (2011). Review of pesticide urinary biomarker measurements from selected US EPA children observational exposure studies. Int J Environ Res Public Health 8:1727-54
14. Garabrant DH, Aylward LL, Berent S, et al. (2009). Cholinesterase inhibition in chlorpyrifos workers: characterization of biomarkers of exposure and response in relation to urinary TCPy. J Expo Sci Environ Epid 19:634-42
15. Gearhart JM, Jepson GW, Clewell HJ, et al. (1994). Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ Health Perspect 102:51-60
16. Gerde P, Scott BR. (2001). A model for absorption of low-volatile toxicants by the airway mucosa. Inhal Toxicol 13:903-29
17. Gerde P, Muggenburg BA, Scott GG, et al. (1998). Local metabolism in lung airways increases the uncertainty of pyrene as a biomarker of polycyclic aromatic hydrocarbon exposure. Carcinogenesis 19: 493-500
18. Griffin P, Mason H, Heywood K, et al. (1999). Oral and dermal absorption of chlorpyrifos: a human volunteer study. Occup Environ Med 56:10-3
19. Guengerich FP. (1994). Analysis and characterization of enzymes. In: Hayes AW, ed. Principles and methods of toxicology. 3rd ed. New York: Raven Press, 1259-314
20. Hays S, Kirman CR. (2013). Quality assurance assessment of the chlorpyrifos physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model. Summit Toxicology Dow Study ID NS000134
21. Hewitt PG, Perkins J, Hotchkiss SA. (2000). Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I: during percutaneous absorption through fresh rat and human skin in vitro. Drug Metab Dispos 28:748-54
22. Hinderliter PM, Price PS, Bartels MJ, et al. (2011). Development of a source-To-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos. Regul Toxicol Pharmacol 61:82-92
23. Hirtz J. (1985). The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol 19:77S-83S
24. Hojring N, Svensmark O. (1976). Carboxylesterases with defferent substrate specificity in human brain extracts. J Neurochem 27: 525-8
25. Hotchkiss JA, Krieger SM, Mahoney KM, et al. (2013). Nose-only inhalation of chlorpyrifos vapor: limited toxicokinetics and determination of time-dependent effects on plasma, red blood cell, brain and lung cholinesterase activity in female CD(SD): Crl rats. Report of The Dow Chemical Company
26. Jewell C, Prusakiewicz JJ, Ackermann C, et al. (2007). The distribution of esterases in the skin of the minipig. Toxicol Let 173:118-23
27. Kaplan JM, Siemers W, Grill HJ. (1997). Effect of oral versus gastric delivery on gastric emptying of corn oil emulsions. Am J Physiol 273(4 Pt 2):R1263-70
28. Karanth S, Pope C. (2000). Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. Toxicol Sci 58:282-9
29. Kim HJ, Bruckner JV, Dallas CE, et al. (1990). Effect of dosing vehicles on the pharmacokinetics of orally administered carbon tetrachloride in rats. Toxicol Appl Pharmacol 102:50-60
30. Kousba AA, Poet TS, Timchalk C. (2007). Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon. Toxicol Sci 95:147-55
31. Kousba AA, Sultatos LG, Poet TS, Timchalk C. (2004). Comparison of chlorpyrifos-oxon and paraoxon acetylcholinesterase inhibition dynamics: potential role of a peripheral binding site. Toxicol Sci 80:239-48
32. Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-84
33. Lowe ER, Poet TS, Rick DL, et al. (2009). The effect of plasma lipids on the pharmacokinetics of chlorpyrifos and the impact on interpretation of blood biomonitoring data. Toxicol Sci 108:258-72
34. Luecke RH, Pearce BA, Wosilait WD, et al. (2007). Postnatal growth considerations for PBPK modeling. J Toxic and Environ Health Part A 70:1027-37
35. Marty MS, Domoradzki JY, Hansen SC, et al. (2007). The effect of route, vehicle, and divided doses on the pharmacokinetics of chlorpyrifos and its metabolite trichloropyridinol in neonatal Sprague-Dawley rats. Toxicol Sci 100:360-73
36. Marty MS, Andrus AK, Bell MP, et al. (2012). Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon. Reg Toxicol Pharmacol 63:209-24
37. Maxwell DM, Brecht KM, Oeill BL. (1987). The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 39:35-42
38. Morgan MK, Jones PA. (2013). Dietary predictors of young children exposure to current-use pesticides using urinary biomonitoring. Food Chem Toxicol 62:131-41
39. Moser VC, Padilla S. (1998). Age- and gender-related differences in the time course of behavioral and biochemical effects produced by oral chlorpyrifos in rats. Toxicol Appl Pharmacol 149:107-19
40. Nolan RJ, Rick DL, Freshour NL, et al. (1984). Chlorpyrifos:pharmacokinetics in human volunteers. Toxicol Appl Pharmacol 73:8-15
41. Olaherty EJ, Kerger BD, Hays SM, Paustenbach DJ. (2001). A physiologically based model for the ingestion of chromium(III) and chromium(VI) by humans. Toxicol Sci 60:196-213
42. Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. (2007). Drugmetabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 39:659-98
43. Padilla S, Marshall RS, Hunter DL, et al. (2005). Neurochemical effects of chronic dietary and repeated high-level acute exposure to chlorpyrifos in rats. Toxicol Sci 88:161-71
44. Poet TS, McDougal JN. (2002). Skin absorption and human risk assessment. Chem Biol Interact 140:19-34
45. Poet TS, Wu H, Kousba AA, Timchalk C. (2003). In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. Toxicol Sci 72:193-200
46. Pope CN, Karanth S, Liu J, Yan B. (2005). Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. Regul Toxicol Pharmacol 42:64-9
47. Poulin P, Haddad S. (2011). Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci. [Epub ahead of print]. doi: 10.1002/jps.22619
48. Price PS, Schnelle KD, Cleveland CB, et al. (2011). Application of a source-To-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. Regul Toxicol Pharmacol 61:23-31
49. Reddy M, Yang RS, Andersen ME, Clewell III HJ. (2005). Physiologically based pharmacokinetic modeling: science and applications (Google eBook). John Wiley & Sons. Available from: http://books.google.com/books?id=mKXLrm7tgLUC&pgis=1 [last accessed 8 May 2014].
50. Rolsted K, Kissmeyer A-M, Rist GM, et al. (2008). Evaluation of cytochrome P450 activity in vitro, using dermal and hepatic microsomes from four species and two keratinocyte cell lines in culture. Arch Dermatol Res 300:11-18
51. Sarkar MA. (1992). Drug metabolism in the nasal mucosa. Pharm Res 9: 1-9
52. Sidell FR, Kaminskis A. (1975). Temporal intrapersonal physiological variability of cholinesterase activity in human plasma and erythrocytes. Clin Chem 21:1961-3
53. Smith JN, Hinderliter PM, Timchalk C, et al. (2014). A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation. Regul Toxicol Pharmacol. [Epub ahead of print]. doi: 10.1016/j.yrtph.2013.10.005
54. Smith JN, Campbell JA, Busby-Hjerpe AL, et al. (2009). Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat. Toxicology 261:47-58
55. Smith JN, Timchalk C, Bartels MJ, et al. (2011). In vitro age-dependent enzymatic metabolism of chlorpyrifos and chlorpyrifos-oxon in human hepatic microsomes and chlorpyrifos-oxon in plasma. Drug Metab Dispos 39:1353-62
56. Song Y, Wang Y, Thakur R, et al. (2004). Mucosal drug delivery:membranes, methodologies, and applications. Crit Rev Ther Drug Carrier Syst 21:195-256
57. Stebbins K. (1996). Dursban F insecticidal chemical: acute oral toxicity study in Fischer 344 rats. Lab Project Number: K-044793-102A: K- 044793-102A1. Unpublished study prepared by The Dow Chemical Co.
58. Svensson CK. (2009). Biotransformation of drugs in human skin. Drug Metab Dispos 37:247-53
59. Timchalk C, Kousba A, Poet, TS. (2002a). Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol Lett 135:51-9
60. Timchalk C, Kousba AA, Poet TS. (2007). An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat. Toxicol Sci 98:348-65
61. Timchalk C, Nolan RJ, Mendrala AL, et al. (2002b). A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci 66:34-53
62. Timchalk C, Poet TS. (2008). Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. NeuroToxicol 29:428-43
63. Timchalk C, Smith JN, Hjerpe A, et al. (2012). Regional brain dosimetry for the organophosphorus insecticide chlorpyrifos in the preweanling rat. In: Parameters for pesticide QSAR and PBPK/PD models for human risk assessment, ACS symposium Series 1099. Washington, DC: American Chemical Society, 195-213
64. Vaccaro JR, Nolan RJ, Murphy PG, et al. (1993). Estimation fo the absorbed dose of chlororpyrifos to adult volunteers following the treatment of carpeting with empire 20 insecticide. Industrial Hygiene Research & Technology, The Dow Chemical Company, Study ID DECO-HEH2.1-1-182
65. Wilson ZE, Rostami-Hodjegan A, Burn JL, et al. (2003). Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-40.
66. Young JF, Luecke RH, Pearce BA, et al. (2009). Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxic and Environmental Health Part A 72:527-40.
67. Zheng Q, Olivier K, Won YK, Pope CN. (2000). Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. Toxicol Sci 55:124-32